



Propoxyphene Napsylate Capsules and Tablets

Eli Lilly and Company
Material Safety Data Sheet

Effective Date: 08-Jun-2004

Section 1 - Chemical Product and Company

Manufacturer:
Eli Lilly and Company
Lilly Corporate Center
Indianapolis, IN 46285

Manufacturer's Emergency Phone:
1-317-276-2000
CHEMTREC:
1-800-424-9300 (North America)
1-703-527-3887 (International)

Common Name: Propoxyphene Napsylate Capsules and Tablets

Chemical Name: Benzeneethanol, alpha-[2-(dimethylamino)-1-methylethyl]-alpha-phenyl-, propanoate (ester), [S-(R*,S*)]-, 2-naphthalenesulfonate (salt), monohydrate

Chemical Name 2: (alphaS,1R)-alpha-[2-(Dimethylamino)-1-methylethyl]-alpha-phenylphenethyl propionate compound with 2-naphthalenesulfonic acid (1:1) monohydrate

Synonym(s): Dextropropoxyphene Napsylate Capsules and Tablets; Propoxyphene; Propoxyphene Napsylate; Propoxyphene Napsylate Capsule Mix; Propoxyphene Napsylate Tablet Mix; Propoxyphene Napsylate Capsules; Propoxyphene Napsylate Tablets; 029352 Formulation

Trademarks(s): Darvon-N

Lilly Item Code(s): PU0391; PU0392; TA1883; TA1886; UC9537

See attached glossary for abbreviations.

Section 2 - Composition / Information on Ingredients

Ingredient	CAS	Concentration %
Propoxyphene Napsylate	26570-10-5	20 - 44
Excipients	NA	56 - 80

Drug Enforcement Administration Status: Controlled Substance, Schedule II for Bulk Propoxyphene and its salts (non-dosage forms)

Drug Enforcement Administration Status: Controlled Substance, Schedule IV for Propoxyphene and its salts in dosage form

Exposure Guidelines:

Propoxyphene napsylate - LEG 200 micrograms/m³ TWA for 12 hours.

Section 3 - Hazards Identification

Appearance: White powder finished as capsules or coated tablets

Physical State: Solid

Odor: Odorless

Emergency Overview



Emergency Overview Effective Date: 04-May-2000

Lilly Laboratory Labeling Codes:

Health 3

Fire 1

Reactivity 0

Primary Physical and Health Hazards: Not hazardous if intact. Corrosive (eyes). Nervous System and Heart Effects.

Caution Statement: Intact Propoxyphene Napsylate Capsules and Tablets are not considered to be a health hazard. The contents of Propoxyphene Napsylate Capsules and Tablets may cause burns or permanent tissue damage to the eyes. Effects of exposure may include convulsions, dizziness, nausea/vomiting, unconsciousness, changes in heart rate/rhythm, shortness of breath, and chemical dependency.

Routes of Entry: Inhalation and skin contact.

Effects of Overexposure: Capsules and tablets are intended for human consumption under guidance of a physician. Capsules and coated tablets are not considered hazardous under normal handling procedures. Based on clinical data, effects of exposure to contents of capsules or powder used to make tablets may include dizziness, nausea/vomiting, respiratory depression, abnormal heart rhythm, and difficulty breathing. Based on animal data, propoxyphene napsylate, may cause burns or permanent tissue damage to the eyes. Dependency may occur with prolonged exposure.

Medical Conditions Aggravated by Exposure: Hypersensitivity to propoxyphene.

Carcinogenicity: Propoxyphene napsylate - No carcinogenicity data found. Not listed by IARC, NTP, ACGIH, or OSHA.

Section 4 - First Aid Measures

Eyes: Hold eyelids open and flush with a steady, gentle stream of water for 15 minutes. See an ophthalmologist (eye doctor) or other physician immediately.

Skin: Remove contaminated clothing and clean before reuse. Wash all exposed areas of skin with plenty of soap and water. Get medical attention if irritation develops.

Inhalation: Move individual to fresh air. Get medical attention if breathing difficulty occurs. If not breathing, provide artificial respiration assistance (mouth-to-mouth) and call a physician immediately.

Ingestion: Do not induce vomiting. Call a physician or poison control center. If available, administer activated charcoal (6-8 heaping teaspoons) with two to three glasses of water. Do not give anything by mouth to an unconscious person. Immediately transport to a medical care facility and see a physician.

Notes to Physician: For treatment of an acute overdose, utilization of an opiate antagonist such as naloxone will produce an immediate effect reversal. Such treatment needs to be provided in a medically-staffed and equipped environment.

Section 5 - Fire Fighting Measures

Flash Point: Not applicable

UEL: No applicable information found

LEL: No applicable information found

Extinguishing Media: Use water, carbon dioxide, dry chemical, foam, or Halon.

Unusual Fire and Explosion Hazards: As a finely divided material, may form dust mixtures in air which could explode if subjected to an ignition source.

Hazardous Combustion Products: May emit toxic fumes when exposed to heat or fire.

Section 6 - Accidental Release Measures

Spills: Vacuum material with appropriate dust collection filter in place. Be aware of potential for dust explosion when using electrical equipment. If vacuum is not available, lightly mist material and remove by sweeping or wet wiping. Wear protective equipment, including eye protection, to avoid exposure (see Section 8 for specific handling precautions). Because this is a controlled substance, special handling and storage requirements must be observed to assure compliance with Drug Enforcement Administration regulations.

Section 7 - Handling and Storage

Material Handling Precautions: Because this is a controlled substance, special handling and storage requirements must be observed to assure compliance with Drug Enforcement Administration regulations.

Storage Conditions: Controlled Room Temperature: 15 to 30 C (59 to 86 F). Controlled Substance Storage Room.

Section 8 - Exposure Controls / Personal Protection

See Section 2 for Exposure Guideline information.

Compressed tablets and intact capsules are not considered hazardous under normal handling procedures and protective equipment is not required. The following are recommended for manufacturing or other situations where exposure to contents may occur.

Respiratory Protection: Use an approved respirator.

Eye Protection: Chemical goggles and/or face shield.

Ventilation: Laboratory fume hood or local exhaust ventilation.

Other Protective Equipment: Chemical-resistant gloves and body covering to minimize skin contact. If handled in a ventilated enclosure, as in a laboratory setting, respirator and goggles or face shield may not be required. Safety glasses are always required.

Additional Exposure Precautions: In production settings, airline-supplied, hood-type respirators are preferred. Shower and change clothing if skin contact occurs. Because this is a controlled substance, special handling and storage requirements must be observed to assure compliance with Drug Enforcement Administration regulations.

Section 9 - Physical and Chemical Properties

Appearance: White powder finished as capsules or coated tablets

Odor: Odorless

Boiling Point: Not applicable

Melting Point: No applicable information found

Specific Gravity: No applicable information found

pH: No applicable information found

Evaporation Rate: No applicable information found

Water Solubility: Slightly soluble

Vapor Density: No applicable information found

Vapor Pressure: No applicable information found

Section 10 - Stability and Reactivity

Stability: Stable at normal temperatures and pressures.

Incompatibility: May react with strong oxidizing agents (e.g., peroxides, permanganates, nitric acid, etc.).

Hazardous Decomposition: May emit toxic fumes when heated to decomposition.

Hazardous Polymerization: Will not occur.

Section 11 - Toxicological Information

Acute Exposure

Data for the active ingredient, propoxyphene napsylate, are reported.

Oral:

Propoxyphene napsylate - Rat, median lethal dose 647 mg/kg, incoordination, reduced activity,

respiratory depression.

Skin:

Propoxyphene napsylate - Rabbit, 500 mg/kg, no deaths or toxicity.

Inhalation:

Propoxyphene napsylate - Rat, 730 mg/m³ for 1 hour, no deaths, reduced activity.

Skin Contact:

Propoxyphene napsylate - Rabbit, nonirritant

Eye Contact:

Propoxyphene napsylate - Rabbit, corrosive

Chronic Exposure

Data for the active ingredient, propoxylate napsylate, are reported.

Target Organ Effects:

Propoxyphene napsylate - Nervous system effects (increased irritability), liver effects (increased liver weight, liver tissue changes), adrenal effects (increased weight), thyroid effects (increased thyroid weight).

Other Effects:

Propoxyphene napsylate - Decreased body weight gain.

Reproduction:

Propoxyphene napsylate - Decreased fertility, decreased viability, and decreased growth rate of offspring at doses toxic to the mother.

Sensitization: No applicable information found.

Mutagenicity: No applicable information found.

Section 12 - Ecological Information

No applicable ecological information found.

Section 13 - Disposal Considerations

Waste Disposal: Because this is a controlled substance, the local Drug Enforcement Administration office must be notified for authority and instructions for disposal. Disposal must be in accordance with applicable federal, state, and local laws and regulations. Dispose of any cleanup materials and waste residue according to all applicable laws and regulations.

Section 14 - Transport Information

Regulatory Organizations:**DOT:** Not Regulated**ICAO/IATA:** Not Regulated**IMO:** Not Regulated

Section 15 - Regulatory Information

Below is selected regulatory information chosen primarily for possible Eli Lilly and Company usage. This section is not a complete analysis or reference to all applicable regulatory information. Please consider all applicable laws and regulations for your country/state.

U.S. Regulations

Propoxyphene napsylate

TSCA - No

CERCLA - Not on this list

SARA 302 - Not on this list

SARA 313 - Not on this list

OSHA Substance Specific - No

EU Regulations

EC Classification

Contains propoxyphene napsylate (C = 20-44%)

Xn (Harmful)

Xi (Irritant)

Risk Phrases

R 22 - Harmful if swallowed.

R 41 - Risk of serious damage to eyes.

Safety Phrases

S 26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.

S 36/37/39 - Wear suitable protective clothing, gloves and eye/face protection.

S 45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible).

Section 16 - Other Information

MSDS Sections Revised: Section 2.

As of the date of issuance, we are providing available information relevant to the handling of this material in the workplace. All information contained herein is offered with the good faith belief that it is accurate. THIS MATERIAL SAFETY DATA SHEET SHALL NOT BE DEEMED TO CREATE ANY WARRANTY OF ANY KIND (INCLUDING WARRANTY OF MERCHANTABILITY OR

FITNESS FOR A PARTICULAR PURPOSE). In the event of an adverse incident associated with this material, this safety data sheet is not intended to be a substitute for consultation with appropriately trained personnel. Nor is this safety data sheet intended to be a substitute for product literature which may accompany the finished product.

For additional information contact:

Eli Lilly and Company
Hazard Communication
317-277-6029

For additional copies contact:

Eli Lilly and Company
1-800-LILLY-Rx (1-800-545-5979)

GLOSSARY:

ACGIH = American Conference of Governmental Industrial Hygienists

AIHA = American Industrial Hygiene Association

BEI = Biological Exposure Index

CAS Number = Chemical Abstract Service Registry Number

CERCLA = Comprehensive Environmental Response Compensation and Liability Act (of 1980)

CHAN = Chemical Hazard Alert Notice

CHEMTREC = Chemical Transportation Emergency Center

DOT = Department of Transportation

EC = European Community

EINECS = European Inventory of Existing Chemical Substances

ELINCS = European List of New Chemical Substances

EPA = Environmental Protection Agency

HEPA = High Efficiency Particulate Air (Filter)

IARC = International Agency for Research on Cancer

ICAO/IATA = International Civil Aviation Organization/International Air Transport Association

IEG = Lilly Interim Exposure Guideline

IMO = International Maritime Organization

Kow = Octanol/Water Partition Coefficient

LEG = Lilly Exposure Guideline

LEL = Lower Explosive Limit

MSDS = Material Safety Data Sheet

MSHA = Mine Safety and Health Administration

NA = Not Applicable, except in Section 14 where NA = North America

NADA = New Animal Drug Application

NAIF = No Applicable Information Found

NCI = National Cancer Institute

NIOSH = National Institute for Occupational Safety and Health

NOS = Not Otherwise Specified

NTP = National Toxicology Program

OSHA = Occupational Safety and Health Administration

PEL = Permissible Exposure Limit (OSHA)

RCRA = Resource Conservation and Recovery Act

RQ = Reportable Quantity

RTECS = Registry of Toxic Effects of Chemical Substances

SARA = Superfund Amendments and Reauthorization Act

STEG = Lilly Short Term Exposure Guideline

STEL = Short Term Exposure Limit

TLV = Threshold Limit Value (ACGIH)

TPQ = Threshold Planning Quantity

TSCA = Toxic Substances Control Act

TWA = Time Weighted Average/8 Hours Unless Otherwise Noted

UEL = Upper Explosive Limit

UN = United Nations

WEEL = Workplace Environmental Exposure Level (AIHA)